Chapter 23: Breast Pathology

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

I have to say, I am genuinely vibrating with excitement for this one.

Oh yeah.

Yeah.

Today, we are doing something a little different, something a bit more targeted.

We are catering this one specifically to the medical learner.

Right.

Maybe you're a med student sitting in the library at, you know, 2 .0 AM surrounded by empty coffee cups, trying to make sense of the world.

Maybe you're a resident looking to brush up.

Or maybe you're just incredibly curious.

Or frankly, maybe you're just one of those insanely curious minds, the kind of person who wants to understand the nuts and bolts of how the human body actually works and how it breaks down.

It is a pleasure to be here.

And you're right.

Today is a focused session.

We are not just talking generally about, you know, health trends or vague wellness concepts.

Not at all.

We are tackling a very specific high yield document.

We are doing a forensic analysis of chapter 23 from the USMLE step one lecture notes on pathology, specifically the 2017 edition.

Right.

And our mission today is pretty clear.

We're going to translate these dense bullet pointed, efficient textbook pages into a clear, logical, and frankly, listenable audio guide.

We're going to move from the basic ouches, the inflammation all the way to the complex neoplasia, the lumps, the bumps, and the scares.

And we should probably set the tone right away.

This is designed as a last minute lecture style review.

What does that mean exactly?

That means we are going to be high yield.

We are focused.

We aren't going to wander off into the weeds of experimental theories that aren't in this specific text.

We are sticking strictly to the provided material to give you the most efficient, accurate download of information possible.

We're following the chapter structure exactly as it appears.

Exactly.

And I'm going to play the role of the enthusiastic learner here.

Essentially, I am the listener's avatar.

I like that.

I'll be asking the questions, stopping us when things get murky and trying to visualize what we're talking about.

I want to know the why, not just the what.

And you, my friend, are the expert guide.

I'm ready.

You're the calm mentor, connecting all the dots for us.

I am ready to connect them.

So let's look at the roadmap.

We have a lot of ground to cover.

We're going to start with section one, inflammatory and traumatic conditions.

The basics.

Then we move into the notoriously confusing world of fibrocystic changes.

That's section two.

And section three covers benign neoplasms.

And then sections four to seven will be the heavy hitters, malignant neoplasms.

That big stuff.

And finally, we'll wrap it all up with section eight, gynecomastia.

It is a logical progression.

It really mirrors the clinical thought process when a patient walks into the clinic.

Is it infection?

Is it a benign change?

Is it a benign tumor or is it?

Oh no, it's cancer.

Okay, let's do it.

Let's unpack this.

Section one, inflammatory and traumatic conditions.

We're starting with something that I think a lot of people have heard of, but maybe don't really understand the pathology of.

Mastitis.

And the text gives us a very specific clinical snapshot.

If I'm a doctor and a patient walks in, what does the classic presentation look like?

Okay, so the classic presentation is a woman who is lactating.

She is breastfeeding.

She presents with acute symptoms.

We're talking about an area of the breast that is erythematous, which is the fancy medical word for red.

Okay.

It's firm to the touch and it's painful.

Okay, so red, firm, painful, and it's happening during breastfeeding.

Now, whenever we see infection in pathology, we have to name the agent.

Who's the bad guy here?

The most common infecting organism is staphylococcus aureus.

Scaphoraeus.

That's a skin bug.

Exactly.

It's part of the normal skin flora.

So what happens is that during breastfeeding, the infant can cause these little

small fissures or cracks in the nipple.

Ouch.

Yeah.

And that trauma creates a portal of entry.

The bacteria that are just sitting there on the skin surface find that open door, they enter the breast tissue, and they find this rich environment, milk to grow in.

That makes perfect physical sense.

You have trauma to the nipple from the infant that creates the portal of entry, and then you have the milk, which is basically a petri dish.

It's the perfect storm.

So you have a nursing mother, red breast, painful,

likely staph aureus, it seems.

Pretty straightforward.

In the real world, you'd probably treat with antibiotics and warm compresses.

Usually, yes.

But the text adds a very specific, and I have to say slightly alarming, note here.

It says the breast is often biopsied.

Yes, that is in the notes.

Why?

I mean, why on earth would you biopsy what looks like a straightforward infection?

That seems aggressive.

This is a crucial clinical nuance, and it's a favorite point for exams.

You biopsy it, because clinically,

acute mastitis can look exactly like something much, much worse.

Inflammatory carcinoma.

Wow.

Okay, that is a scary mimic.

It is the scariest mimic in breast pathology.

Inflammatory breast cancer, which we will definitely discuss in detail later, presents almost identically to mastitis, a red, swollen, warm, firm breast.

How can they look so similar?

Well, the redness in mastitis is from vasodilation due to the infection.

It's the body fighting the bacteria.

The redness in inflammatory carcinoma is from tumor emboli, little clumps of cancer blocking the lymphatic vessels in the skin.

But to the naked eye,

they can look identical.

So the takeaway is, if you treat for mastitis and it doesn't resolve quickly, or if the presentation is a little atypical, maybe the patient isn't even lactating, you cannot just assume it's a simple infection.

You absolutely cannot.

You have to rule out cancer.

You cannot leave that to chance.

That is a very high yield point.

Never assume redness is just an infection in the breast without follow -up.

Okay, so now let's say we do that biopsy.

We're looking under the microscope at true mastitis.

What are we seeing?

You're seeing the standard soldiers of inflammation.

You'll see acute inflammation, which means neutrophils are just swarming the area.

First responders.

The first responders.

You'll also see chronic inflammation.

And in some cases, the text notes that you'll see abscess formation.

And an abscess is basically a walled off collection of pus, right?

Precisely.

It's the body trying to contain the infection to wall it off from the rest of the tissue.

Okay, so that's mastitis.

Now let's talk about the second condition in this section.

Fat necrosis.

I feel like this one is the prankster of breast pathology.

That's a good way to put it.

It is the great mimic.

Why do you say that?

Because the setup is so deceptive.

A patient comes in, maybe she feels a lump while she's in the shower, or maybe she goes for a routine mammogram, and the radiologist sees a discrete lesion with calcifications.

And calcifications on mammogram is basically the universal code for, we suspect, cancer.

It's the big red flag, exactly.

It looks scary.

It feels like a mass.

It looks like cancer on the imaging.

But the cause is completely benign.

So what is the cause?

Usually trauma.

Trauma.

Like what kind of trauma are we talking about?

A car accident?

Yes, a seat belt injury is a classic example.

Or a fall.

Or even prior surgery on the breast, like a biopsy or a lumpectomy.

So the trauma physically damages the tissue?

Specifically, it damages the adipose tissue, the fat.

You have to remember, the breast is largely composed of fat.

Trauma causes necrosis, which just means death of those fat cells.

And this is where we need to put on our CSI hats.

We have a mass that looks like cancer.

We biopsy it.

What is the microscopic evidence that proves it's actually just fat necrosis?

The text lists a specific sequence of events.

It does.

It lists four specific findings you'd be looking for.

First, and most obviously, you see fat necrosis itself.

Under the microscope, dead fat cells lose their nuclei and they look like these sort of ghostly outlines.

Stooky.

Indeed.

Second, you see the body's cleanup crew.

So you see chronic inflammation.

The immune system is sending in cells to try to clear away all the debris from the dead fat cell.

Makes sense.

And the third one?

Third, you see fibrosis.

That's just scar tissue forming as part of the healing process.

Okay.

And the fourth one?

The text mentions a very specific pigment.

Yes.

Hemocedarin deposits.

Hemocedarin.

That's an iron pigment, right?

Where is that coming from?

Yes.

It comes from the breakdown of red blood cells.

Think about it.

Trauma causes bleeding, even if it's just a little bit.

The blood cells break down.

They release their iron.

And the macrophages, the cleanup cells, eat that iron.

It shows up as this brown pigment called hemocedarin.

So it's a clue.

It tells you there was bleeding there in the past, which aligns perfectly with the history of trauma.

It's the smoking gun, microscopically.

And finally, calcification.

Why does dead fat calcify?

This seems to be the part that makes it look so much like cancer on the mammogram.

Yeah, it's a process called saponification.

Saponification.

Like making soap.

Exactly like making soap.

It's a chemical reaction.

The fatty acids that are released from the destroyed fat cells bind with calcium salts that are just floating around in the body fluids.

It literally turns into a soapy, chalky deposit.

And that calcium is radio opaque.

It's dense.

Which is why it lights up bright white on the mammogram, mimicking malignant calcifications.

Wow.

So to summarize this whole section,

mastitis is an infection that mimics inflammatory carcinoma, and fat necrosis is a trauma response that mimics a tumor mass.

Both are benign, but both force you to prove they aren't cancer.

Correct.

It is all about ruling out the worst case scenario.

That's a recurring theme in breast pathology.

All right, let's move on to section two, fibrocystic changes.

This is a big topic, and it is one where terminology really matters.

I noticed that.

The text makes a point to say fibrocystic changes rather than fibrocystic disease.

That is a really important shift in thinking.

We used to call it a disease, but it is so incredibly common in women of reproductive age, the text says specifically age 20 to 50, that we now consider it more of a variation of normal physiology.

So it's not really a disease in the classic sense of something being broken.

Exactly.

It's more like an exaggerated response of the breast tissue to the normal monthly hormonal cycles.

Okay, that makes sense.

Where does this usually happen in the breast?

Is there a specific spot?

The text specifies the upper outer quadrant.

Which tracts?

Right.

That's where the bulk of the glandular breast tissue is located.

And clinically, what is the patient complaining of?

What brings them in?

Usually a palpable mass or nodularity or just a general lumpiness to the breast.

It's often described as having a cobblestone texture.

Okay.

Now here is where it gets technical.

The text says we have to classify these changes into two main buckets,

non -proliferative and proliferative.

This is the most critical job of the pathologist when they get a biopsy of fibrocystic changes.

Making this distinction is everything.

Why?

I mean, if they're all just benign fibrocystic changes, why does it matter which bucket they fall into?

It matters because of risk stratification, as the text states.

Because they carry varying degrees of risk for breast cancer, it is important to identify each type histologically.

So we're essentially trying to predict the future.

In a way, yes.

We want to know if this particular set of changes puts this patient at a higher risk for developing a malignancy down the road.

It dictates how we manage them, how closely we watch them.

Okay, that is a huge point.

So let's break down the non -proliferative changes first.

These are the safe ones, right?

The ones with no increased risk.

Correct.

The text lists four key types here.

If a patient has only these changes, their risk of breast cancer is effectively zero, or to be more precise, no higher than the general population.

So you can reassure the patient.

Walk us through them.

What's the first one?

First is fibrosis.

This is just an increase in stromal collagen.

It's basically scarring.

So it can feel firm.

It can feel very firm, so it can mimic a tumor on clinical exam and on ultrasound, but pathologically, it is completely harmless.

Okay.

What's number two?

Cysts.

And specifically, the text uses the phrase blue domed cysts.

Blue domed.

That's a very specific visual.

What does that mean?

It refers to their gross appearance when you see them directly, like in surgery.

When a surgeon exposes them, they look like these little blue domes because the fluid inside them reflects light in a specific way through the stretched out cyst wall.

And the text notes these can usually be diagnosed simply by ultrasound.

If the ultrasound shows a simple thin walled fluid filled sac, it's benign.

No biopsy needed.

Okay.

The third one on the non -proliferative list is one that confused me.

Apocrine metaplasia.

Now usually when I hear a metaplasia in pathology, like in the lung with smokers or Barrett's esophagus,

I think danger.

I think pre -cancerous.

And you were right to be wary of that word.

Usually it is a big warning sign.

But the breast is the great exception to the rule.

Apocrine metaplasia, which is when the normal ductal cells change to look like the cells of African sweat glands.

They get these big pink granular cells is completely benign in the breast.

No increased risk.

So apocrine metaplasia in the breast equals no increased risk.

That is a tricky one.

It is a very common board question trap because it completely defies the general rule of pathology that we all learn.

Good to know.

And the fourth one.

Microcalcifications.

Wait a minute.

Didn't we just say a few minutes ago that calcifications on a mammogram are scary and make us think of cancer?

They can be.

And they are often the reason for the biopsy in the first place.

They occur in malignant processes for sure.

But the text is reminding us here that they also occur in many benign processes.

I see.

So seeing calcifications alone doesn't diagnose cancer.

It just means something is happening.

And often it's just benign calcification of secretions within the ducts.

Got it.

So fibrosis, cysts, apocrine metaplasia, and microcalcifications.

If you see these on a biopsy report, you can breathe a sigh of relief.

No increased risk.

Exactly.

Now we move to the other side of the coin.

The proliferative changes.

This is the risk ladder.

Okay.

Let's look at table 32 from the notes.

It breaks down the relative risk very clearly.

Right.

So we just said the non -proliferative stuff is no increase.

Now, if we step up to a relative risk of 1 .5 to 2 times the risk of the normal population, we see three things listed.

For sure.

Sclerosing adenosis, ductal hyperplasia, the usual type, and papillomas.

Let's define sclerosing adenosis.

That sounds pretty ominous.

Let's break the word down.

Sclerosing means hardening or scarring.

Adenosis means too many glands or adenoids.

So you have a proliferation of small glands that are trapped and compressed by a fibrotic scarred stroma.

How on earth do you tell that apart from cancer?

It sounds a lot like cancer.

Too many glands, scar tissue, feels hard.

Histologically, the absolute key is the myoepithelial layer.

Explain that layer for us.

In the breast, all the normal ducts and glands are lined by two distinct layers of cells.

There's an inner layer of luminal cells, the ones that would make milk, and an outer layer of myoepithelial cells.

Myo.

Epithelium.

Myo like muscle.

Well, exactly.

They are contractile.

They're the cells that squeeze the milk out.

In benign conditions, even messy looking ones like sclerosing adenosis, that outer myoepithelial layer is always intact.

It's a continuous ring.

And in cancer?

In invasive cancer, that layer is lost.

The cancer cells have broken through it.

Okay, so that is a key concept.

Myoepithelial layer present equals benign.

If that seal is broken, it's invasive cancer.

If it's intact, it's benign.

Precisely.

You can think of it as your safety seal.

The pathologist will even use special stains to highlight those myoepithelial cells to be absolutely sure.

Okay, then we have ductal hyperplasia.

This is when the cells lining the ducts just start multiplying too much.

Yes, and there's a spectrum.

You have usual ductal hyperplasia, which is in this 1 .5 to 2 times risk category.

It's just more cells, but they're architecturally jumbled and disorganized.

But the cells start looking weird.

If they start showing atypia, if they become more uniform and start forming rigid cookie cutter -like spaces, then we climb the ladder.

And that brings us to the top of the risk ladder for these benign changes.

Atypical ductal or lobular hyperplasia.

Here, the risk jumps significantly to 4 to 5 times that of the general population.

These are lesions that look almost like cancer,

specifically carcinoma in situ, but they don't quite meet all the criteria to be called that.

So they're on the verge.

They are very much on the verge.

The text mentions differentiating atypical lobular hyperplasia, ALH, from lobular carcinoma in situ, LCIS.

How do they tell them apart?

Yeah, how do they draw that line?

It is purely a numbers game.

It's based on the percentage of the assini, the little milk producing units within a lobule that are involved that are filled with these atypical cells.

If it's extensive and fills up most of the assini, it gets called LCIS.

If it's less extensive, it's called ALH.

That sounds like a really fine line.

It sounds like a judgment call for the pathologist.

It can be.

But that call is what changes the diagnosis from benign high -risk lesion to malignant in situ disease.

It has huge implications for the patient's treatment.

Before we leave this section, let's look at table 2323.

It gives us a great mental checklist to distinguish fibrocystic change from breast cancer clinically.

This seems super useful for physical exams.

It is very high yield for the clinic.

It contrasts the two based on three main factors.

First, symmetry.

Fibrocystic changes are often bilateral.

You feel lumpiness in both breasts.

Cancer is usually unilateral, just in one breast.

Makes sense.

What's second?

Second, number.

Fibrocystic changes typically present with multiple nodules, that cobblestone feeling.

Cancer is usually a single discrete mass.

And third?

Third, hormonal response.

This is a big one.

Fibrocystic changes often vary with the menstrual cycle.

They get painful and engorged right before a period.

Right.

Cancer does not care about your menstrual cycle.

It grows regardless of the time of the month.

And what about pregnancy?

The table mentions that.

Fibrocystic changes may regress or change during pregnancy due to the massive hormonal shifts.

Cancer, on the other hand, does not regress.

Perfect.

So that covers the lumps.

Now let's talk about the bumps.

Section three, benign neoplasms.

These are true tumors, but they're benign.

Correct.

We have three main players here that the text focuses on.

Fibrodinoma, philodes tumor, and intraductal papilloma.

Let's start with the most common one.

Fibrodinoma.

Who gets this?

This is the tumor of the young woman.

The text states it is the most common benign tumor in women under the age of 35.

And how does it feel?

What's the classic description on exam?

It's very discumptive.

It is a palpable, round, rubbery mass.

And the key feature is that it's movable.

I've heard it described as a breast mouse

because it kind of slips away from under your fingers when you try to pin it down.

That is a perfect description.

It isn't tethered or fixed to the surrounding tissue like cancer often is.

It feels very contained and mobile.

And if we cut it open grossly or microscopically,

what do we see?

We have figure 23 to 1 here in the notes that shows it.

Figure 23 to 1 shows a very specific pattern.

Cleft -like spaces.

A fibrodinoma is what we call a biphasic tumor.

Biphasic meaning two parts.

Exactly.

It has two components that are both proliferating.

The benign stroma, which is the connective tissue, and the benign glands, or ducts.

Because the stroma grows so much and so fast, it compresses the ducts into these flattened, slit -like, cleft -like spaces.

That's the hallmark.

OK.

So young patient, movable, rubbery mass, cleft -like spaces on biopsy.

That's classic fibrodinoma.

Now, what is the phyldis tumor?

Think of the phyldis tumor as the fibrodinoma's older, potentially meaner cousin.

Yes, it usually presents in older patients.

The text says women in their 50s, typically.

And meaner.

Why meaner?

Because it can be benign, but it can also be malignant.

We used to call the malignant version cystosarcoma phyloades.

And the text notes that even the benign ones have a tendency for local recurrence if they aren't completely excised.

And the name phyloades, the text mentions it's leaf -like.

Phyloades actually comes from the Greek word for leaf.

Histologically, you see increased stromal cellularity.

So there are just more cells packed into that connective tissue part compared to a fibrodinoma.

And this stromal overgrowth pushes into the cystic spaces, creating these large, broad, leaf -like projections.

So to recap, fibrodinoma is younger women, benign stroma, simple cleft -like spaces.

Phyloades is older women, more cellular stroma, big leaf -like patterns, and potential for malignancy.

Correct.

That's the key differential diagnosis there.

And the third benign tumor, introductal papilloma.

This is the bleeder.

The bleeder.

Yes, this is the classic cause of a bloody or serosanguineous nipple discharge in a woman.

That has to be a terrifying symptom for a patient.

I mean, seeing blood coming from the nipple would set off every single alarm bell?

It does, absolutely.

But in this case, the introductal papilloma is benign.

It's a small, delicate, finger -like growth that sits within one of the large, lactiferous ducts or sinuses right under the nipple.

So it's right near the exit.

Exactly.

And because it's so delicate and right in the duct, it can get twisted or infarcted, and it bleeds into the duct, that blood then comes out the nipple.

And again, the big question.

How do we know it's not papillary carcinoma, which is a cancer?

It's our old friend, the safety seal.

The text notes specifically that the myoepithelial layer is preserved in the stalks of the papilloma.

That's what distinguishes it from papillary carcinoma, where that protective outer layer is absent.

I'm really sensing a theme here.

The myoepithelial layer is your friend.

It is one of the most reliable and important rules in all of breast pathology.

OK.

We have cleared the benign hurdles.

Now we have to enter the serious territory.

Section four, malignant neoplasms.

The landscape here is sobering.

Carcinoma of the breast is the most common cancer in women.

The text cites a one in nine incidence in the USA.

One in nine.

That is a staggering number.

It means essentially everyone knows someone who has been affected by this.

And it's the second most common cause of cancer death in women.

Interestingly, the text makes a point to note that the incidence is higher in the United States than in Japan, which hints at environmental or lifestyle factors playing a significant role.

Let's talk about those risk factors.

What is the fuel for this fire?

What drives breast cancer?

Estrogen.

That's the one word answer.

Unusually long or intense exposure to estrogens is the unifying theme for the vast majority of breast cancers.

So anything that gives your body more estrogen exposure over a lifetime is going to increase your risk.

Exactly.

Let's just look at the list in the text.

Risk increases with age.

That's true for most cancers.

Reproductive history.

A long length of reproductive life.

That means early menarche, starting your period, young and late menopause.

That simply results in more years of the breast being exposed to estrogen cycling.

And null parity.

Is there ever having children?

Right.

Why does having children lower the risk?

Pregnancy interrupts the monthly cycle of estrogen -driven proliferation.

It essentially gives the breast tissue a long break from those constant hormonal fluctuations.

Got it.

And obesity.

Why is obesity a risk factor?

Because fat cells adipose tissue contain an enzyme called aromatase.

And what aromatase does is it converts androgen precursors, which are male -type hormones, into estrogen.

So your fat is making estrogen.

Yes.

It's called peripheral conversion.

So more body fat equals higher systemic estrogen levels, especially after menopause.

And of course, exogenous estrogens, like hormone replacement therapy, add to that total load.

Then there's the genetic component.

Hereditary influences account for about 5 to 10 percent of all breast cancers.

Having first degree relatives with breast cancer is a major risk factor.

And the specific genes.

We hear about BRCA all the time.

BRCA1 and BRCA2.

The text gives their locations.

BRCA1 is on chromosome 17q21, and BRCA2 is on chromosome 13q12 .3.

What do these genes actually do?

I think a lot of people assume they're cancer genes, like they cause cancer directly.

But that's not right, is it?

They're actually anti -cancer genes normally.

That's exactly right.

They are tumor suppressor genes.

Their job is to be the mechanics of the cell.

The text says they are involved in the error -free repair of DNA double -strand breaks.

So they're the DNA repair crew.

Precisely.

If you have a mutation in BRCA1 or 2, your repair crew is broken.

DNA damage accumulates.

Mutations happen.

And eventually, that leads to cancer.

The text also mentions another one, TP53.

Germ -lying mutations in TP53 cause life -roll -many syndrome, which predisposes people to many cancers, including breast cancer at a young age.

OK, so we know the risk factors.

Now let's talk about the cancer itself.

Section 5 covers carcinoma in situ and invasive types.

We have to start with the precursors.

Carcinoma in situ, or CIS.

This means the cancer cells have formed.

They look malignant under the microscope.

But they are contained.

They have not broken through the basement membrane.

They're still in the duct.

They're still in the duct, or the lobule.

They haven't invaded the surrounding stroma yet.

And there are two main flavors.

DCIS, ductal, and LCIS, lobular.

Right.

And there is a 35 % rule mentioned in the text for both of them.

But the implications of that rule are very, very different for each.

OK, go on.

About 35 % of women with untreated DCIS will go on to develop invasive cancer.

And importantly, it usually happens in the same quadrant of the same breast where the DCIS was found.

So DCIS is a direct precursor in that specific spot.

It's a ticking time bomb right there in that location.

Yes, exactly.

Now contrast that with LCIS.

About 35 % of women with LCIS will develop invasive cancer.

But it can be in either breast.

Oh, wow.

So LCIS isn't a direct precursor in one spot.

It's more of a marker of total body risk or total breast tissue risk.

That's the perfect way to think about it.

It predicts a bilateral risk.

It tells you the soil is bad in both gardens, so to speak.

And a cancer could pop up on either side.

That's a huge distinction.

Now let's say the cancer does break through the basement membrane.

We are now dealing with invasive carcinoma.

What is the most common type by far?

Invasive ductal carcinoma, or IDC, it accounts for over 80 % of cases.

It's the classic breast cancer.

What does this look like if you're a surgeon or a pathologist holding the specimen?

It is ugly.

It is a stellate mass, that means it's star -shaped, with these spiky edges that reach out and pull on the surrounding tissue.

It's typically white, tan, and gritty.

Or gritty.

Yes.

The classic description is that cutting, it feels like cutting through an unripe pear.

That grittiness comes from something called the desmoplastic stroma.

What is desmoplasia?

It is a fibrous response from the body.

The tumor provokes the body to lay down dense scar tissue all around it.

That's what makes the lump feel so rock hard on a physical exam.

And microscopically.

Figure 23 -2 helps us here.

You see malignant tumor cells trying to form ducts, but they're trapped in that dense pink fibrous stroma.

That's the desmoplasia.

We also have to talk about the receptors.

This is huge for determining treatment.

For invasive ductal carcinoma, the text says about 70 % are ERPR positive, meaning they have estrogen and progesterone receptors.

And about 30 % overexpress a receptor called HER2.

Okay, now contrast all of that with the second most common type,

invasive lobular carcinoma, ILC.

ILC is less common, about 5 -10 % of cases.

Morphologically, it is completely different.

The cells are small and bland looking.

Bland meaning they don't look super crazy or angry under the microscope.

Right, they don't scream cancer at you cytologically.

But the key pattern, the thing you have to know for ILC, is single file.

Like soldiers marching in a line.

Exactly, or Indian file.

The cells don't form ducts or clumps.

They invade the tissue by marching in a single file line, one after another.

Why do they do that?

Is there a reason?

Yes.

It's fundamentally due to a loss of cell -to -cell adhesion.

They're missing a glue molecule called echidherin, so they can't stick together to form a duct.

They just slip through the tissue individually.

And behavior -wise, how is it different from ductal?

It is often multifocal and bilateral.

Again, echoing the nature of its precursor, LCIS.

And receptor -wise, these are usually ERPR positive, but they very rarely over -expressed HER2.

So ductal is the hard, gritty stellate mass that forms ducts.

Lobular is the sneaky single file line of cells that can be in both breasts.

That's a perfect summary.

Now the text lists some special histologic variants.

I love these because they have such distinct personalities.

Let's run through them.

First up, mucinous or colloid carcinoma.

This one looks really distinct under the microscope.

You see these little clusters of bland tumor cells floating in these big pools of mucin.

That sounds spiky.

It is.

It's very gelatinous.

But clinically, it's good news.

It tends to occur in older women and has a much better prognosis than typical IDC.

It's almost always hormone receptor positive.

Next on the list,

tubular carcinoma.

Also, excellent prognosis.

In fact, the text notes it rarely metastasizes.

The cells form these very well -differentiated, open tubules that look almost like normal ducts.

Okay, how about medullary carcinoma?

This one is a paradox.

Microscopically, it looks ugly.

The cells are very pleomorphic.

They have weird shapes, different sizes, and they form what are called syncytial groups, which are big clumps of cells.

But UT, it has a better prognosis.

Wait, why, if it looks so aggressive, why is the prognosis better?

Look at the company it keeps.

The text notes that the tumor is surrounded by a dense lymphocytic host response.

So the immune system sees it?

The immune system sees it and is actively fighting it.

You see sheets of lymphocytes infiltrating the tumor.

That robust host response is likely why it behaves better than its ugly appearance would suggest.

That is fascinating.

The body is fighting back.

And finally, the worst one of the bunch,

inflammatory carcinoma.

This is the most aggressive form of breast cancer.

A very poor prognosis.

How does it present?

We touched on this.

It mimics mastitis, as we said at the very start.

A red, warm, edematous breast.

But the cause isn't bacteria.

No.

The cause is extensive tumor invasion into the dermal lymphatics.

The cancer cells clog up the lymph drainage channels of the skin itself.

And if the lymph can't drain, fluid backs up.

Fluid backs up, causing swelling or edema.

And this leads to that classic clinical description, peau d 'orange.

French for skin of an orange.

The skin becomes thickened and dimpled just like an orange peel.

Why is it dimpled like that?

What's the mechanism?

It's a mechanical thing.

Figure 23 -3 in the book illustrates this perfectly.

The skin puffs up with all that fluid, the edema, but it is tethered down to the deeper tissue by the suspensory ligaments of Cooper.

So the skin swells out between the ligaments.

Exactly.

The ligaments hold it down in points, creating that classic deepled texture.

That is such a vivid image.

And it's a critical physical exam sign not to miss.

Absolutely.

Peau d 'orange equals advanced cancer until proven otherwise.

Before we move to staging, we need to talk about section 6.

Paget disease of the nipple.

This is another one of those skin changes that signals deep trouble.

So what is it?

It is the intraepidermal spread of tumor cells.

Basically, you have cancer cells from an underlying DCIS or invasive ductal carcinoma deep in the breast that crawl their way up the ducts and invade the skin of the nipple and areola.

And what does the patient see?

What does it look like?

It looks just like eczema.

You get ulceration, oozing, crusting, and fissuring of the nipple.

So the take -home message is if a woman has what looks like eczema on her nipple, that isn't getting better with creams.

You have to think Paget disease.

You have to think about an underlying breast carcinoma.

The text is very clear.

It's almost always associated with an underlying cancer.

And under the microscope,

figure 23 -4 shows this.

You see what are called Paget cells.

These are large malignant tumor cells sitting inside the epidermis among the normal skin cells.

They often have a clear halo surrounding their nucleus.

They just look completely out of place.

A halo.

OK, so nipple eczema that won't go away equals check for underlying cancer.

Correct.

You have to biopsy it.

Section seven, staging prognosis and treatment.

This is the what now section.

This is what determines everything for the patient.

Prognosis depends on a hierarchy of factors.

The text lists them in order of importance.

What is number one, the single most important factor?

Axillary lymph node status, period.

Whether or not the cancer has spread to the lymph nodes in the armpit is the single most important prognostic factor.

And how do we check that?

We used to just rip them all out in a procedure called an axillary dissection.

Now we're much smarter.

We do a sentinel node biopsy, SNB.

How does that work?

We inject a blue dye or a radioactive tracer near the tumor to find the very first lymph node, the sentinel, that drains the breast.

We remove just that one node and check it.

If it's clear of cancer, we can spare the rest.

And that spares the patient a lot of complications like lymphedema, the swelling of the arm.

A huge improvement in quality of life.

Okay, what's next in the hierarchy after notes?

Tumor size.

Simply put, smaller is better than histologic grade.

How ugly or undifferentiated the cells look under the microscope.

And then the receptors.

We touched on this, but let's really clarify the treatment implications.

Right.

If a tumor is ERPR positive, meaning it has estrogen and or progesterone receptors, we can use endocrine therapy.

Likewise.

Drugs that block estrogen's effect like camoxifen.

Because the tumor essentially feeds on estrogen.

Exactly.

You starve it of its fuel.

And what about HER2neu?

HER2 overexpression is associated with more aggressive behavior.

It used to be a very bad prognostic sign.

But now we have Trastuzumab, which you might know as Herceptin.

Right.

It is a monoclonal antibody that specifically targets the HER2 receptor on the cancer cells.

So it turns an aggressive marker into a therapeutic target.

Precisely.

It was a complete game changer in breast cancer treatment.

The text also mentions a couple of other biomarkers for decision making.

UPA and PAI -1.

What are those?

Yes.

Urokinase plasminogen activator and its inhibitor.

These are measured in the tumor tissue to help guide treatment decisions specifically in node -negative breast cancer patients to figure out who might benefit from chemotherapy.

And for monitoring for metastasis, for recurrence.

We use blood tests for tumor markers like CA15 -3, CA27 .29, and CEA.

These are not for screening the general population.

They are for monitoring patients who already have metastatic disease to see if the therapy is working or if the cancer is growing back.

Got it.

Okay.

We are in the homestretch.

Yeah.

Section 8.

Gynecomastia.

The male breast.

It happens.

It does.

Gynecomastia is the benign enlargement of the male breast.

It can be unilateral or bilateral.

What's the basic mechanism?

Men have a little bit of estrogen.

They do.

But usually androgen, specifically testosterone, dominates.

Gynecomastia happens when that balance shifts.

The estrogen to androgen ratio increases.

Estrogen wins the tug of war.

And microscopically, what does it look like?

Does it look like female breast tissue?

Sort of.

You see ductal hyperplasia and elongation.

So the ducts grow.

But, and this is a key point, you generally do not see lobules.

Why not?

Males don't usually develop lobules because they don't produce progesterone in the same way and aren't primed to produce milk.

So you see ducts but no lobules.

Okay.

So ducts but no lobules.

What causes this hormonal imbalance?

The text groups the causes into three main categories.

Physiologic, pathologic, and drugs.

Physiologic means it can happen at normal life stages.

Yes.

In newborns, from mom's hormones crossing the placenta during puberty when there's a hormone storm.

And in the elderly, as testosterone levels naturally drop.

Okay.

What about the pathologic causes?

The disease states?

The big one is cirrhosis of the liver.

The liver is responsible for metabolizing estrogen.

If the liver is failing, estrogen builds up in the body.

What else?

Also Kleinfelter syndrome, which is a genetic condition, xxy, and certain pituitary tumors like prolactinomas.

And finally, drugs.

There are a few famous ones for this.

Yes.

The notorious ones listed in the text are spironolactone, which is a diuretic often used for heart failure, and ketoconazole, which is an antifungal medication.

So spironolactone and ketoconazole, watch out for those.

Indeed.

They are classic causes.

Wow.

We have covered a massive amount of ground.

From the simple redness of mastitis all the way to the Indian file of lobular carcinoma.

It is an incredibly dense chapter.

If we had to synthesize this for the listener, what are the really big picture takeaways?

I think there are three.

First, the crucial distinction between inflammation and neoplasia.

Both can present as lumps or pain, but the history and the biopsy are absolutely key to telling them apart.

Okay.

Second, the concept of in situ versus invasive.

That basement membrane is the line in the sand between a contained problem and one that can spread.

Right.

And third, the critical role of histology.

We saw it over and over again with fibrocystic changes.

Apocrine metaplasia is benign, but atypical hyperplasia is high risk.

We saw it with cancer.

Tubular has a great prognosis.

Inflammatory has a terrible one.

You cannot treat breast pathology without understanding the microscopic architecture.

For me, the biggest aha moment was definitely apocrine metaplasia being benign.

That just goes against my metaplasia's bad instinct from every other part of pathology.

That's a classic exception.

And also just how terrifying fat necrosis can be mimicking cancer so perfectly on every level, from the physical exam to the mammogram.

It keeps clinicians humble, that's for sure.

So here is a final provocative thought for our listeners to mull over.

We often think of breast pathology as purely a lump issue.

We're trained to feel for lumps in the shower.

Doctors feel for lumps on exams.

But as we saw with inflammatory carcinoma and badger disease,

sometimes the most dangerous signs are actually skin changes, redness, and eczema -like rash, dimpling.

It really changes how you look at the physical exam.

It's not just about touch.

It's about sight.

That is a vital perspective.

The skin often tells the story of what is happening in the tissue underneath it.

Well, thanks for diving deep with us.

This has been a Last Minute Lecture Production.

Keep learning.

See you next time.